ProNAi Therapeutics is a pre-clinical development stage biopharmaceutical company focused on bringing to market novel Nucleic Acid inhibitors. It has a proprietary DNAi approach to design uniquely formulated drugs directly from known cancer and other complex genetic disease targets. The therapeutics will be internally developed to the FDA IND filing status and subsequent early phase clinical trials in humans. Upon establishing clinical efficacy in humans, the validated therapeutics will be partnered with larger pharmaceutical firms for late stage clinical development, manufacturing and marketing. The firm has an expanded intellectual property portfolio covering the formulary drugs and the DNAi drug mechanism.